AAP
ALLO icon

Arax Advisory Partners’s Allogene Therapeutics ALLO Stock Holding History

Arax Advisory Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.6K Buy
44,033
+43,199
+5,180% +$94.9K ﹤0.01% 2801
2026
Q1 		$2.04K Buy
+834
New +$1.67K ﹤0.01% 3103
2025
Q4 		– Sell
-37,401
Closed -$46.4K – 4091
2025
Q3 		$46.4K Buy
+37,401
New +$44.6K ﹤0.01% 1862

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Arax Advisory Partners's ALLO Position: Q2 2026 in Review

Arax Advisory Partners increased its Allogene Therapeutics (ALLO) stake by 5,180% in Q2 2026, buying an estimated $94.9K and bringing the position to 44,033 shares worth $91.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

Arax Advisory Partners first reported a position in ALLO in Q3 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Arax Advisory Partners held 44,033 shares of Allogene Therapeutics worth $91.6K as of Q2 2026.
  • Arax Advisory Partners bought 43,199 Allogene Therapeutics shares in Q2 2026, an estimated $94.9K.
  • Allogene Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2801 holding.
  • Arax Advisory Partners first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.